General physicians' perspectives on SGLT2 inhibitors for heart failure
Internal Medicine Journal · 2024-09 · 54 (9) · 1483-1489
DOI: 10.1111/imj.16440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 03.07.2024. Verfasst von Lung E Teng und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Medicine Unit, Alfred Health, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, General Practitioners. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are novel agents for heart failure (HF) and are now recommended in guidelines. Understanding general physicians' perspectives can help to optimise utilisation of this new medication.
Aim
To understand the clinical concerns and barriers from general physicians about prescribing SGLT2is in a general medicine cohort.
Methods
A questionnaire exploring clinicians' experience, comfort level and barriers to prescribing SGLT2is in patients with HF, incorporating two clinical scenarios, was disseminated to Internal Medicine Society of Australia and New Zealand members over a 2‐month period.
Results
Ninety‐eight participants responded to the questionnaire (10.8% response rate). Most respondents (66.3%) were senior medical staff. Most participants worked in metropolitan settings (64.3%) and in public hospital settings (83.7%). For HF with reduced ejection fraction, 23.5% of participants reported prescribing SGLT2is frequently (defined as prescribing SGLT2is frequently over 75% of occasions). For HF with preserved ejection fraction, 57.1% of participants reported prescribing SGLT2is less than 25% of the time. Almost half of the participants (44%) expressed a high level of familiarity with therapeutic knowledge of SGLT2is, while 47% indicated high familiarity with potential side effects. Patient complexity, cost of medications and discontinuity of care were identified as important barriers. Euglycemic diabetic ketoacidosis was the side effect that caused the most hesitancy to prescribe SGLT2is in 48% of the respondents.
Conclusion
General physicians in Australia and Aotearoa New Zealand are familiar with the therapeutic knowledge and side effects of SGLT2is. Patient complexity, medication cost and discontinuity of care were significant barriers to the use of SGLT2is for HF among general physicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Medicine Unit, Alfred Health, Monash University, Melbourne, Victoria, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Department of Pharmacy, Alfred Health, Monash University, Melbourne, Victoria, Australia.
- Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Lung E Teng, Ar K Aung, Ingrid Hopper
Zitieren
APA
Teng, L. E., Lammoza, N., Aung, A. K., Thayaparan, A., Vasudevan, S., Edwards, G., Hormiz, M., Gibbs, H., & Hopper, I. (2024). General physicians' perspectives on SGLT2 inhibitors for heart failure. Internal Medicine Journal, 54(9), 1483-1489. https://doi.org/10.1111/imj.16440
Vancouver
Teng LE, Lammoza N, Aung AK, Thayaparan A, Vasudevan S, Edwards G, et al. General physicians' perspectives on SGLT2 inhibitors for heart failure. Internal Medicine Journal. 2024;54(9):1483-1489. doi:10.1111/imj.16440
BibTeX
@article{Teng2024,
author = {Teng, Lung E and Lammoza, Noor and Aung, Ar K and Thayaparan, Archana and Vasudevan, Swetha and Edwards, Gail and Hormiz, Maria and Gibbs, Harry and Hopper, Ingrid},
title = {General physicians' perspectives on SGLT2 inhibitors for heart failure},
journal = {Internal Medicine Journal},
year = {2024},
volume = {54},
number = {9},
pages = {1483--1489},
doi = {10.1111/imj.16440}
}
EUVIMED